Rituximab: 13 open questions after 20years of clinical use

Volume: 53, Pages: 38 - 46
Published: Feb 1, 2017
Abstract
Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but despite 20years of intensive use, it remains a drug with a number of still obscure characteristics and unanswered questions. These include the mechanism of action and of resistance, the optimal schedule, the interaction with chemotherapy, as well as predictive factors for response rate and duration. Despite being very well tolerated, the question of its long...
Paper Details
Title
Rituximab: 13 open questions after 20years of clinical use
Published Date
Feb 1, 2017
Volume
53
Pages
38 - 46
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.